<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00856674</url>
  </required_header>
  <id_info>
    <org_study_id>OPL01-CCL2</org_study_id>
    <nct_id>NCT00856674</nct_id>
  </id_info>
  <brief_title>Safety Study of of Intravenous CCL2-LPM in Patients With IgA Nephropathy</brief_title>
  <official_title>A Dose-Escalating Phase I Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Intravenous OPL-CCL2-LPM in Patients With IgA Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Osprey Pharmaceuticals USA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Osprey Pharmaceuticals USA, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of several dose levels of CCL2-LPM in
      patients with IgA Nephropathy who have high levels of protein in the urine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In spite of adequate blood pressure control and diet, 30 percent of patients with IgA
      nephropathy continue to secrete large amounts of protein in the urine and have a high
      likelihood of progressing to end-stage renal disease over 5-10 years and eventually requiring
      dialysis or kidney transplant. In IgA nephropathy, the injured kidney tissue secretes a
      messenger that recruits white blood cells (leukocytes) into the kidney. This messenger is the
      chemokine, CCL2. As a consequence CCL2 also is excreted into the urine and can be measured as
      evidence of inflammation in the kidney. This study evaluates the safety of a new potential
      therapy,CCL2-LPM (leukocyte population modulator), for IgA nephropathy. CCL2-LPM is composed
      of the messenger chemokine, CCL2, fused to an enzyme that inhibits protein production by the
      leukocytes and prevents the leukocytes from migrating into the kidney. The CCL2 end of the
      molecule targets only a small subset of leukocytes that have the corresponding receptor for
      CCL2 on the surface. After CCL2 binds to its receptor it is drawn inside the cell and carries
      the enzyme into the cell. The targeted cells are prevented from entering the kidney and
      causing further damage. Thus, CCL2-LPM may interrupt the ongoing cycle of inflammation that
      leads to end-stage renal disease.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study terminated due to resources and slow enrollment; not due to safety
  </why_stopped>
  <start_date>March 2009</start_date>
  <completion_date type="Anticipated">June 2010</completion_date>
  <primary_completion_date type="Anticipated">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity</measure>
    <time_frame>30 days after last dose of study drug</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: urine protein/creatinine, urine CCL2/creatinine, sCRP change, change in leukocyte subsets by flow cytometry analysis</measure>
    <time_frame>over 30 day period</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>IGA Nephropathy</condition>
  <condition>Proteinuria</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>OPL-CCL2-LPM</intervention_name>
    <description>CCL2-LPM
intravenous 0.001 mg/kg, 0.01 mg/kg, 0.05 mg/kg, 0.1 mg/kg, 0.5 mg/kg, 1 mg/kg
2 doses one week apart</description>
    <other_name>CCL2-LPM</other_name>
    <other_name>CCL2-SA1 fusion protein</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy proven IgA nephropathy

          -  GFR &gt; 30 mL/min

          -  Urinary protein &gt; 700 mg/day

          -  Stable serum creatinine

          -  Urine CCL2/creatinine &gt; 250 pg/mg

          -  Stable doses of medications

          -  ACEI and/or ARB maximized to control hypertension and proteinuria

        Exclusion Criteria:

          -  Other causes of nephropathy

          -  Pregnant or nursing females

          -  Prednisone &gt; 10 mg/day

          -  Other prohibited medications

          -  BP &gt; 140/90

          -  BMI &gt; 35

          -  Concurrent infection requiring treatment

          -  Clinical significant concurrent medical conditions

          -  Known allergy or sensitivity to formulation ingredients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent Pichette, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Maisonneuve-Rosemont, Univeristy of Montreal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michelle Hladunewich, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bryan Curtis, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eastern Health, HSC, Memorial University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eastern Health, HSC, Memorial University</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hoptial Maisonneuve-Rosemont</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>McDonald JR, McManaman JL, Yong VW. The therapeutic potential of chemokine-toxin fusion proteins. IDrugs. 2001 Apr;4(4):427-42.</citation>
    <PMID>16015483</PMID>
  </reference>
  <reference>
    <citation>Eardley KS, Zehnder D, Quinkler M, Lepenies J, Bates RL, Savage CO, Howie AJ, Adu D, Cockwell P. The relationship between albuminuria, MCP-1/CCL2, and interstitial macrophages in chronic kidney disease. Kidney Int. 2006 Apr;69(7):1189-97.</citation>
    <PMID>16609683</PMID>
  </reference>
  <reference>
    <citation>McIntosh LM, Barnes JL, Barnes VL, McDonald JR. Selective CCR2-targeted macrophage depletion ameliorates experimental mesangioproliferative glomerulonephritis. Clin Exp Immunol. 2009 Feb;155(2):295-303. doi: 10.1111/j.1365-2249.2008.03819.x. Epub 2008 Nov 25.</citation>
    <PMID>19040610</PMID>
  </reference>
  <reference>
    <citation>Reich HN, Troyanov S, Scholey JW, Cattran DC; Toronto Glomerulonephritis Registry. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol. 2007 Dec;18(12):3177-83. Epub 2007 Oct 31.</citation>
    <PMID>17978307</PMID>
  </reference>
  <reference>
    <citation>Morii T, Fujita H, Narita T, Koshimura J, Shimotomai T, Fujishima H, Yoshioka N, Imai H, Kakei M, Ito S. Increased urinary excretion of monocyte chemoattractant protein-1 in proteinuric renal diseases. Ren Fail. 2003 May;25(3):439-44.</citation>
    <PMID>12803507</PMID>
  </reference>
  <reference>
    <citation>Rovin BH. The chemokine network in systemic lupus erythematous nephritis. Front Biosci. 2008 Jan 1;13:904-22. Review.</citation>
    <PMID>17981599</PMID>
  </reference>
  <reference>
    <citation>Nair R, Walker PD. Is IgA nephropathy the commonest primary glomerulopathy among young adults in the USA? Kidney Int. 2006 Apr;69(8):1455-8.</citation>
    <PMID>16531983</PMID>
  </reference>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2009</study_first_submitted>
  <study_first_submitted_qc>March 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2009</study_first_posted>
  <last_update_submitted>June 1, 2010</last_update_submitted>
  <last_update_submitted_qc>June 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Barbara K. Finck, M.D., Senior Vice President and Chief Medical Officer</name_title>
    <organization>Osprey Pharmaceuticals USA, Inc.</organization>
  </responsible_party>
  <keyword>IgA nephropathy</keyword>
  <keyword>chemokine fusion protein</keyword>
  <keyword>leukocyte population modulator</keyword>
  <keyword>phase-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Proteinuria</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

